LENANGIO 25MG
Lenangio 25mg contains Lenalidomide as an active substance which belongs to thalidomide analogue. Lenangio 25mg contains some pharmacological activities like immuno modulatory, anti-neoplastic, & anti-angiogenesis. Lenangio 25mg is a prescription medicine; used under the supervision of medical oncologist. Lenangio 25mg is used by combining with dexamethasone.
Lenalidomide
Lenangio
25mg
Dr. Reddy’s
Lenangio indication
The most common indications of Lenangio 25mg are;
Multiple myeloma: Lenangio 25mg should be used in combination with dexamethasone.
Myelodysplastic syndrome: Lenangio 25mg is used to treat this condition
Mantle cell lymphoma: Lenangio 25mg is used for this condition, if patients are not responding to the Bortezomib treatment.
Lenangio mechanism
Lenangio includes in the restraint of tumor rot factor alpha arrangement, which support the T-cells and causes lessening serum levels of cytokines vascular endothelial development factor and fundamental fibroblast development factor.
Lenangio is additionally engaged with the preclusion of angiogenesis.
Lenalidomide is additionally empowered G1 cell cycle capture and apoptosis of ruinous cells.
Lenangio Dosage & administration
The usual prescribed dose of Lenalidomide in myelodysplastic syndromes is 10mg should be given as once a day.
For renal damaged patients;
In Patients with CrCl >60ml/min should not require dosage adjustment of Lenalidomide.
In Patients with CrCl 30 to 60ml/min, 5mg of Lenalidomide should be given orally as once a day.
In Patient with CrCl <30ml/min, 2.5mg of Lenalidomide should be administered orally as a once a day.
Dosage variation
Thrombocytopenia
Drops to <500/mcL, therapy should be postponed.
Back to > or equal to 500/mcL, treatment should be continuing to 5mg/day.
Neutropenia
Drops to <500/mcL, therapy should be postponed.
Back to > or equal to 500/mcL, treatment should be continuing to 5mg/day.
Multiple myeloma
In this condition, Lenalidomide is concomitant with dexamethasone.
The usual dose of Lenalidomide is 25mg should be administered as once daily on day 1 to 21.
The dose of dexamethasone;
40mg of dexamethasone should be followed on day 1 to 4, 9 to 12 & 17 to 20 of each 28-day cycles.
Patient with >75 years, 20mg of dexamethasone should be recommended on day 1, 8, 15, & 22.
Mantle cell lymphoma
The advised dose of Lenalidomide for this condition is 25mg should be administered orally as once daily.
For renal damaged patients:
Patient with CrCl 30 to 60ml/min, 10mg of Lenalidomide should be administered as once daily.
Patient with CrCl <30ml/min, 15mg of Lenalidomide should be used for q48hr.
Pediatrics:
The potency & effectiveness of Lenalidomide has not been evaluated in pediatric patients with age of <18 years.
Lenangio side effects
Second primary malignancies, Liver toxicity, Hypersensitivity reactions, Tumor lysis syndrome, Tumor flare reactions, Thyroid disorders, Fetal toxicity, Hematological toxicity, Elevation of mortality rate
Common side effects
Fatigue, Asthenia, Pyrexia, Diabetes mellitus, Rash, Insomnia, Depression, Deep vein thrombosis, Myocardial infraction, Renal failure, Squamous cell carcinoma, Basal cell carcinoma, Pain, Diarrhea, Dyspepsia, Bone pain, Neck pain, Muscle weakness, pain, Respiratory infections, UTI, Influenza, Sepsis, Headache, Anemia, Loss of appetite, Hypokalemia, Hyperglycemia, Hypocalcaemia, Dehydration, Gout
Lenangio warning
The most common life-threatening condition like :
Embryo fetal damage
Hypersensitivity reactions
Venous & arterial thromboembolism
Blood clotting effects
Hematological disorders
For all these conditions, some supportive measures should be used and provide safety measures.
